Abstract:BACKGROUND Gastric cancer (GC) is one of the most common and deadliest types of cancer worldwide due to its delayed diagnosis and high metastatic frequency, but its exact pathogenesis has not been fully elucidated. ETS homologous factor (EHF) is an important member of the ETS family and contributes to the pathogenesis of multiple malignant tumors. To date, whether EHF participates in the development of GC via the c-Met signaling pathway remains unclear. AIM To investigate the role and mechanism of EHF in the occurrence and development of GC. METHODS The expression of EHF mRNA in GC tissues and cell lines was measured by quantitative PCR. Western blotting was performed to determine the protein expression of EHF, c-Met, and its downstream signal molecules. The EHF expression in GC tissues was further detected by immunohistochemical staining. To investigate the role of EHF in GC oncogenesis, small interfering RNA (siRNA) against EHF was transfected into GC cells. The cell proliferation of GC cells was determined by Cell Counting Kit-8 and colony formation assays. Flow cytometry was performed following Annexin V/propidium iodide (PI) to identify apoptotic cells and PI staining to analyze the cell cycle. Cell migration and invasion were assessed by transwell assays. RESULTS The data showed that EHF was upregulated in GC tissues and cell lines in which increased expression of c-Met was also observed. Silencing of EHF by siRNA reduced the proliferation of GC cells. Inhibition of EHF induced significant apoptosis and cell cycle arrest in GC cells. Cell migration and invasion were significantly inhibited. EHF silencing led to c-Met downregulation and further blocked the Ras/c-Raf/extracellular signal-related kinase 1/2 (Erk1/2) pathway. Additionally, phosphatase and tensin homolog was upregulated and glycogen synthase kinase 3 beta was deactivated. Moreover, inactivation of signal transducer and activator of transcription 3 was detected following EHF inhibition, leading to inhibition of the epithelial-to-mesenchymal transition (EMT). CONCLUSION These results suggest that EHF plays a key role in cell proliferation, invasion, apoptosis, the cell cycle and EMT via the c-Met pathway. Therefore, EHF may serve as an antineoplastic target for the diagnosis and treatment of GC.

Crosstalk Between Mesenchymal-Epithelial Transition Factor and Epithelial Growth Factor Receptor in the Development of Resistance to Anticancer Drugs

MicroRNAs and Long Non-coding RNAs in c-Met-Regulated Cancers

HGF/c-Met Axis: the Advanced Development in Digestive System Cancer

Blockage of ETS Homologous Factor Inhibits the Proliferation and Invasion of Gastric Cancer Cells Through the C-Met Pathway

[Research Progress in Hepatocyte Growth Factor/Mesenchymal-epithelial Transition Factor Signaling Pathway:Effects and Mechanisms on Resistance to Targeted Therapy for Non-small Cell Lung Cancer].

[Advances in Mesenchymal to Epithelial Transition Factor Signaling Pathway and Inhibitors].

Research Progress of C-Met Signaling Pathway and Antagonists

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer

[Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer].

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer

Role of C-Met in the Progression of Human Oral Squamous Cell Carcinoma and Its Potential As a Therapeutic Target.

[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer].

Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression

Role of HGF/c-Met Signaling in Tumorigenesis and the Tumor Therapy Therewith

The Progress of Antibody-Based Anti-Tumor Drugs Targeting HGF/c-Met Signaling Pathway

Targeting the hedgehog pathway in MET mutation cancers and its effects on cells associated with cancer development

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response

Crosstalk Between Autophagy and Epithelial-Mesenchymal Transition and Its Application in Cancer Therapy